Phenomic

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. The company has demonstrated clear in vivo proof-of-concept for this program building confidence in scTx’s ability to identify novel high-impact, druggable targets. In October 2020, the company secured a $6.00M Seed Round investment from investors including AV8 Ventures, Viva BioInnovator, Cantos Ventures, CTI Life Sciences Fund, Garage Capital, Hike Ventures, Toronto Innovation Acceleration Partners. Phenomic's focus on innovative solutions for cancer treatment makes it an exciting prospect in the Biotechnology and Information Technology industries since its establishment in 2017.